Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (238)	11/23/1998 7:18:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1386

The Elan SNX-111 head trauma trial was partnered with Warner Lambert. I can't help but speculate that WLA is now in the market for a head trauma drug. They maybe gun shy. But, the SNX-111 trial was terminated quite early. Maybe they found a better candidate drug :-) John de C

To: Dr. John M. de Castro who wrote (238)	11/24/1998 8:42:00 AM
From: Richard Huth	Read Replies (2) \| Respond to of 1386

This is good news for PARS in the long run. But I am not convinced that the abandoning of SNX-111 will support PARS share price in the near future. I guess just the opposite will be the case. With every possible new drug in TBI failing, it won't be easy to convince investors that PARS is going to make the run. In the eyes of investors this new failure will make it even less likely that HU-211 will survive PhIII. Investros staying aside for another few month and just watching might be the result. Something we do not like as we want to see the stock move upwards again. Richard